The data from NHIRD of Taiwan also demonstrated better survival rate in patients with NSCLC/T2DM who received EGFR TKI with metformin compared with those who did not receive metformin (Supplementary Table 3). Here, EGFR is linked to non-small cell lung carcinoma.